

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934**

Dated August 6, 2015

Commission File Number 001-36421

AURINIA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

N/A

(Translation of Registrant's Name)

#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250) 708-4272

(Address and telephone number of registrant's principle executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 6, 2015

Aurinia Pharmaceuticals Inc.

By: /s/ Michael R. Martin

Name: Michael R. Martin

Title: Chief Operating Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	News Release – Aurinia Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference

Aurinia Pharmaceuticals to Present at the Canaccord Genuity 35th Annual Growth Conference

VICTORIA, British Columbia--(BUSINESS WIRE)--August 6, 2015--Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that its Chief Operating Officer Michael R. Martin will present a corporate overview of the company at the Canaccord Genuity 35th Annual Growth Conference, taking place August 12-13 in Boston at the Intercontinental Hotel.

Aurinia Presentation Details

Date: Thursday, August 13, 2015

Time: 9:30 a.m. Eastern

Location: InterContinental Boston Hotel

Webcast: <http://wsw.com/webcast/canaccord18/auph>

About Aurinia

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

Visit www.auriniapharma.com for more information.

CONTACT:

Aurinia Pharmaceuticals Inc.

Company Contact:

Stephen Zaruby, 250-708-4293

President & Chief Executive Officer

szaruby@auriniapharma.com

or

Investor & Media Contact:

Michael R. Martin, 250-708-4272

Chief Operating Officer

mmartin@auriniapharma.com